Antibe Therapeutics, Inc.

Ordinary Shares International Reporting
Verified Company Profile 9/08/2017
Contact Info
  • 15 Prince Arthur Avenue
  • Toronto, ONT M5R 1B2
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Jun 30, 2017 Quarterly Report
CIK 0001583682
Fiscal Year End 3/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: Canada
Year of Inc. 2013
Employees 46 a/o Mar 31, 2017
Company Officers/Contacts
Daniel Legault CEO
John Wallace CSO
Alain Wilson CFO
Scott Curtis VP, Business Development
David Vaughan Chief Development Officer
Beth Chin Finance Manager
Company Directors
Walt Macnee Chairman
Roderick Flower
Daniel Legault
Samira Sakhia
John Wallace
Service Providers
Accounting/Auditing Firm
Ernst & Young LLP
11th km National Road Athens-Lamia
Securities Counsel Investor Relations Firm

Not Available
Company History
  • Sponsored for OTCQX by Merriman Capital, Inc. on 9/15/2014.
ATBPF Security Details
Share Structure
Market Value1 $11,407,712 a/o Oct 17, 2017
Authorized Shares Unlimited a/o Sep 08, 2017
Outstanding Shares 162,967,313 a/o Sep 08, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 121,474,519 a/o Sep 08, 2017
Par Value Not Available
Transfer Agent(s)
Shareholders of Record Not Available
Non US Stock Exchange Listing
ATE - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 13,334 (0%)
Sep 29, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security